Feocromocitoma

Referências

Principais artigos

Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019 Aug 8;381(6):552-65. Resumo

Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42.Texto completo  Resumo

Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014 Jan-Feb;38(1):7-41.Texto completo  Resumo

Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.Texto completo  Resumo

Plouin PF, Amar L, Dekkers OM, et al; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-10.Texto completo  Resumo

Pang Y, Liu Y, Pacak K, et al. Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies. Cancers (Basel). 2019 Mar 28;11(4). Resumo

Artigos de referência

1. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019 Aug 8;381(6):552-65. Resumo

2. Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42.Texto completo  Resumo

3. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014 Jan-Feb;38(1):7-41.Texto completo  Resumo

4. Lloyd RV, Osamura RY, Klöppel G, et al, eds. WHO classification of tumours of endocrine organs: WHO classification of tumours. 4th ed., Vol. 10. Lyon, France: International Agency of research on Cancer (IARC); 2017.

5. Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol. 2017 Sep;28(3):213-27. Resumo

6. Gabi JN, Milhem MM, Tovar YE, et al. Severe Cushing syndrome due to an ACTH-producing pheochromocytoma: a case presentation and review of the literature. J Endocr Soc. 2018 May 24;2(7):621-30.Texto completo  Resumo

7. Jiang J, Zhang L, Wu Z, et al. A rare case of watery diarrhea, hypokalemia and achlorhydria syndrome caused by pheochromocytoma. BMC Cancer. 2014 Jul 31;14:553.Texto completo  Resumo

8. Ronen JA, Gavin M, Ruppert MD, et al. Glycemic disturbances in pheochromocytoma and paraganglioma. Cureus. 2019 Apr 27;11(4):e4551.Texto completo  Resumo

9. Sinnott B, Wu S, Sarne D, et al. Presentation of an unsuspected pheochromocytoma as acute aortic valvular insufficiency and diabetes mellitus type 2. Endocrinologist. 2006 Nov/Dec;16(6):335-9.Texto completo

10. Davison AS, Jones DM, Ruthven S, et al. Clinical evaluation and treatment of phaeochromocytoma. Ann Clin Biochem. 2018 Jan;55(1):34-48.Texto completo  Resumo

11. Berends AMA, Buitenwerf E, de Krijger RR, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018 May;51:68-73. Resumo

12. Plouin PF, Gimenez-Roqueplo AP. Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis. 2006 Dec 8;1:49.Texto completo  Resumo

13. Yeo H, Roman S. Pheochromocytoma and functional paraganglioma. Curr Opin Oncol. 2005 Jan;17(1):13-8. Resumo

14. Liu P, Li M, Guan X, et al. Clinical syndromes and genetic screening strategies of pheochromocytoma and paraganglioma. J Kidney Cancer VHL. 2018 Dec 27;5(4):14-22. Resumo

15. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992 Jan;147(1):1-10. Resumo

16. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9;346(19):1459-66. Resumo

17. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006 Aug;1073:30-7. Resumo

18. Eisenhofer G. Screening for pheochromocytomas and paragangliomas. Curr Hypertens Rep. 2012 Apr;14(2):130-7. Resumo

19. Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991 Sep;40(3):544-56. Resumo

20. Pattarino F, Bouloux PM. The diagnosis of malignancy in phaeochromocytoma. Clin Endocrinol (Oxf). 1996 Feb;44(2):239-41. Resumo

21. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005 Dec 1;23(34):8812-8. Resumo

22. Reisch N, Peczkowska M, Januszewicz A, et al. Pheochromocytoma: presentation, diagnosis, and treatment. J Hypertens. 2006 Dec;24(12):2331-9. Resumo

23. Parenti G, Zampetti B, Rapizzi E, et al. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012;2012:872713.Texto completo  Resumo

24. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis. 2006 Nov 14;1:45.Texto completo  Resumo

25. Pomares FJ, Canas R, Rodriguez JM, et al. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf). 1998 Feb;48(2):195-200. Resumo

26. Maher ER. Von Hippel-Lindau disease. Curr Mol Med. 2004 Dec;4(8):833-42. Resumo

27. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981 Dec 31;305(27):1617-27. Resumo

28. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet. 2001 Apr 14;357(9263):1181-2. Resumo

29. Rogowski-Lehmann N, Geroula A, Prejbisz A, et al. Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocr Connect. 2018 Sep 1 [Epub ahead of print].Texto completo  Resumo

30. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34.Texto completo  Resumo

31. Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations. Endocr Pract. 2009 Jul-Aug;15(5):450-3. Resumo

32. Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011 Jun;40(2):295-311. Resumo

33. Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.Texto completo  Resumo

34. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553-8.Texto completo  Resumo

35. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002 Mar 20;287(11):1427-34.Texto completo  Resumo

36. Eisenhofer G, Golstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66.Texto completo  Resumo

37. Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin A in the management of patients with pheochromocytoma. Clin Endocrinol. 2006 Sep;65(3):287-93. Resumo

38. Plouin PF, Amar L, Dekkers OM, et al; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-10.Texto completo  Resumo

39. Mazzaglia PJ. Hereditary pheochromocytoma and paraganglioma. J Surg Oncol. 2012 Oct 1;106(5):580-5. Resumo

40. Rana HQ, Rainville IR, Vaidya A. Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma. Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):166-76. Resumo

41. Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015 Jan;17(1):70-87.Texto completo  Resumo

42. Havekes B, King K, Lai EW, et al. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010 Feb;72(2):137-45.Texto completo  Resumo

43. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):62-72. Resumo

44. Terzolo M, Ali A, Pia A, et al. Cyclic Cushing's syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma. J Endocrinol Invest. 1994 Dec;17(11):869-74. Resumo

45. Bayraktar F, Kebapcilar L, Kocdor MA, et al. Cushing's syndrome due to ectopic CRH secretion by adrenal pheochromocytoma accompanied by renal infarction. Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):444-7. Resumo

46. Smith SL, Slappy AL, Fox TP, et al. Pheochromocytoma producing vasoactive intestinal peptide. Mayo Clin Proc. 2002 Jan;77(1):97-100. Resumo

47. Bravo EL, Gifford RW Jr. Pheochromocytoma. Endocrinol Metab Clin North Am. 1993 Jun;22(2):329-41. Resumo

48. Martin SS, Karra R, Mark DB. Pheochromocytoma presenting as a fever of unknown origin. Am J Med. 2011;124:e5-6. Resumo

49. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553-8.Texto completo  Resumo

50. Václavík J, Stejskal D, Lacnák B, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens. 2007 Jul;25(7):1427-31. Resumo

51. Drenou B, Le Tulzo Y, Caulet-Maugendre S, et al. Pheochromocytoma and secondary erythrocytosis: role of tumor erythropoietin secretion. Nouv Rev Fr Hematol. 1995;37(3):197-9. Resumo

52. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma: a review of its utility and pitfalls. Arch Intern Med. 1992 Jun;152(6):1193-7. Resumo

53. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med. 2001 Feb 20;134(4):315-29.Texto completo  Resumo

54. Jacobson AF, Deng H, Lombard J, et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010 Jun;95(6):2596-606.Texto completo  Resumo

55. Sinnott B, Hatipoglu B. Adrenal incidentaloma in pregnancy. Endocrinologist. 2005 Jul/Aug;15(4):205-8.Texto completo

56. Sarathi VL, Lila AR, Bandgar TR, et al. Pheochromocytoma and pregnancy: a rare but dangerous combination. Endocr Pract. 2010 Mar-Apr;16(2):300-9. Resumo

57. Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet. 1984 May-Jun;9(3):239-51. Resumo

58. Kocak S, Aydintug S, Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas. Int Surg. 2002 Jul-Sep;87(3):191-4. Resumo

59. Nicholson JP Jr, Vaughn ED Jr, Pickering TG, et al. Pheochromocytoma and prazosin. Ann Int Med. 1983 Oct;99(4):477-9. Resumo

60. Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with phaeochromocytoma. World J Surg. 2002 Aug;26(8):1037-42. Resumo

61. National Center for Biotechnology Information. PubChem Database. Metyrosine. November 2019 [internet publication].Texto completo

62. Tada K, Okuda T, Yamashita K. Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine combination chemotherapty and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res. 1998;49(6):295-7. Resumo

63. Cryer PE. Diseases of the sympathochromaffin system. In: Felig P, Frohman LA, eds. Endocrinology and metabolism, 4th ed. New York: McGraw-Hill; 2001:525-51.

64. Fung MM, Viveros OH, O'Connor DT. Diseases of the adrenal medulla. Acta Physiol (Oxf). 2008 Feb;192(2):325-35. Resumo

65. Petri BJ, van Eijck CH, de Herder WW, et al. Phaeochromocytomas and sympathetic paragangliomas. Br J Surg. 2009 Dec;96(12):1381-92.Texto completo  Resumo

66. Kaye DR, Storey BB, Pacak K, et al. Partial adrenalectomy: underused first line therapy for small adrenal tumors. J Urol. 2010 Jul;184(1):18-25. Resumo

67. Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002 Jun;16(3):359-69. Resumo

68. Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg. 2004 Oct;91(10):1259-74. Resumo

69. Brandao LF, Autorino R, Laydner H, et al. Robotic versus laparoscopic adrenalectomy: a systematic review and meta-analysis. Eur Urol. 2014 Jun;65(6):1154-61. Resumo

70. Plouin PF, Duclos JM, Soppelsa F, et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001 Apr;86(4):1480-6.Texto completo  Resumo

71. Pacak KL, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102. Resumo

72. Akiba M, Kodama T, Ito Y, et al. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg. 1990 May-Jun;14(3):317-24. Resumo

73. Adjallé R, Plouin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009 Sep;41(9):687-96. Resumo

74. Niemeijer ND, Alblas G, van Hulsteijn LT, et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51.Texto completo  Resumo

75. Pang Y, Liu Y, Pacak K, et al. Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies. Cancers (Basel). 2019 Mar 28;11(4). Resumo

76. Edström Elder E, Hjelm Skog AL, Höög A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 2003 Apr;29(3):278-83. Resumo

77. Breen W, Bancos I, Young WF Jr, et al. External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol. 2017 Nov 22;3(1):25-9.Texto completo  Resumo

78. Pacak K, Fojo T, Goldstein DS, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst. 2001 Apr 18;93(8):648-9.Texto completo  Resumo

79. Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014 Dec 1;135(11):2711-20. Resumo

80. Kayano D, Kinuya S. Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging. 2018 Aug;52(4):254-65. Resumo

81. Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of high-specific-activity ¹³¹I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019 May;60(5):623-30. Resumo

82. van Hulsteijn LT, Niemeijer ND, Dekkers OM, et al. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501.Texto completo  Resumo

83. Fishbein L, Bonner L, Torigian DA, et al. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Horm Metab Res. 2012 May;44(5):405-10. Resumo

84. Yip L, Lee JE, Shapiro SE. Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr;198(4):525-34. Resumo

85. Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaechromocytomas and paragangliomas. Anaesthesia. 2005 May;60(5):439-44. Resumo

86. Proye C, Thevenin D, Cecat P, et al. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery. 1989 Dec;106(6):1149-54. Resumo

87. Kizer JR, Koniaris LS, Edelman JD, et al. Pheochromocytoma crisis, cardiomyopathy, and hemodynamic collapse. Chest. 2000 Oct;118(4):1221-3. Resumo

88. Radtke WE, Kazmier FJ, Rutherford BD, et al. Cardiovascular complications of pheochromocytoma crisis. Am J Cardiol. 1975 May;35(5):701-5. Resumo

89. Steinsapir J, Carr AA, Prisant LM, et al. Metyrosine and pheochromocytoma. Arch Intern Med. 1997 Apr 28;157(8):901-6. Resumo

90. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6.Texto completo  Resumo

91. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004 Sep;11(3):423-36.Texto completo  Resumo

92. Huang KH, Chung SD, Chen SC, et al. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institution. Int J Urol. 2007 Mar;14(3):181-5. Resumo

93. Hamidi O, Young WF Jr, Gruber L, et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2017 Nov;87(5):440-50. Resumo

94. Yoshida S, Hatori M, Noshiro T, et al. Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma. Arch Orthop Trauma Surg. 2001 Nov;121(10):598-600. Resumo

95. Mei L, Khurana A, Al-Juhaishi T, et al. Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review. Horm Metab Res. 2019 Jul;51(7):451-7. Resumo

96. Tan SG, Koay CK, Chan ST. The use of vasopressin to treat catecholamine-resistant hypotension after pheochromocyoma removal. Anaesth Intensive Care. 2002 Aug;30(4):477-80. Resumo

97. Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. 2005 Jul;258(1):55-66. Resumo

98. Amar L, Lussey-Lepoutre C, Lenders JW, et al. Management of endocrine disease: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol. 2016 Oct;175(4):R135-45.Texto completo  Resumo

99. Kudva YC, Young WF Jr, Thompson GB, et al. Adrenal incidentaloma: an important component of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. Endocrinologist. 1999 Mar;9(2):77-80.Texto completo

100. Bernini GP, Vivaldi MS, Argenio GF, et al. Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. J Endocrinol Invest. 1997 Feb;20(2):65-71. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal